Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

1.6K
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
1.6K
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias01:25

ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias

1.1K
Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...
1.1K
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

650
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
650
Dysrhythmias VII: Nursing Management of Dysrhythmias01:25

Dysrhythmias VII: Nursing Management of Dysrhythmias

555
Nursing management of dysrhythmias involves the following:AssessmentSubjective Assessment:The initial step involves gathering patient-reported symptoms such as dizziness, palpitations, and chest discomfort. It is crucial to collect a detailed history, including previous heart conditions, current medication use, and lifestyle factors like caffeine and alcohol consumption.Objective Assessment:This involves observing clinical signs such as jugular venous distention, cool and pale skin, and...
555
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

811
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
811
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

2.0K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
2.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association between interventional cardiologist practice characteristics, CABG use, and clinical outcomes.

European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery·2026
Same author

Scope and Outcome of Early Repolarization Syndrome in Unexplained Cardiac Arrest: Insights From the National HiRO Registry.

Circulation. Arrhythmia and electrophysiology·2026
Same author

Epinephrine Challenge: Long-Term Evaluation of Test Performance for the Evaluation of Unexplained Cardiac Arrest and Familial Sudden Death.

JACC. Clinical electrophysiology·2026
Same author

Pace and Ablate or Pace Then Ablate: Defining the Risk of Concomitant AV Node Ablation and Pacemaker Implantation Using a Probability Based Approach.

Circulation. Arrhythmia and electrophysiology·2026
Same author

2026 HRS/AHA/APHRS/EHRA/IDSA/LAHRS/PACES/STS expert consensus statement update on cardiovascular implantable electronic device lead management and extraction.

Heart rhythm·2026
Same author

Burst Exercise Stress Testing in Catecholaminergic Polymorphic Ventricular Tachycardia.

JAMA cardiology·2026

Related Experiment Video

Updated: Apr 19, 2026

Tilt Testing with Combined Lower Body Negative Pressure: a "Gold Standard" for Measuring Orthostatic Tolerance
14:09

Tilt Testing with Combined Lower Body Negative Pressure: a "Gold Standard" for Measuring Orthostatic Tolerance

Published on: March 21, 2013

22.2K

Does any therapy really work for neurocardiogenic syncope?

Nathaniel M Hawkins, Andrew D Krahn1

  • 1Division of Cardiology, University of British Columbia, Vancouver, Canada. akrahn@mail.ubc.ca.

Cardiology Journal
|December 20, 2014
PubMed
Summary
This summary is machine-generated.

Treatments for neurocardiogenic syncope show limited impact on recurrence. Lifestyle changes are favored for their low cost and lack of side effects, while specific drugs and pacing may help select patients.

More Related Videos

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration
07:59

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration

Published on: April 4, 2022

1.9K
Author Spotlight: A Unique Mouse Model of Asphyxia-Induced Cardiac Arrest
07:18

Author Spotlight: A Unique Mouse Model of Asphyxia-Induced Cardiac Arrest

Published on: April 14, 2023

2.5K

Related Experiment Videos

Last Updated: Apr 19, 2026

Tilt Testing with Combined Lower Body Negative Pressure: a "Gold Standard" for Measuring Orthostatic Tolerance
14:09

Tilt Testing with Combined Lower Body Negative Pressure: a "Gold Standard" for Measuring Orthostatic Tolerance

Published on: March 21, 2013

22.2K
Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration
07:59

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration

Published on: April 4, 2022

1.9K
Author Spotlight: A Unique Mouse Model of Asphyxia-Induced Cardiac Arrest
07:18

Author Spotlight: A Unique Mouse Model of Asphyxia-Induced Cardiac Arrest

Published on: April 14, 2023

2.5K

Area of Science:

  • Cardiology
  • Neurology
  • Clinical Medicine

Background:

  • Neurocardiogenic syncope (NCS) treatments are evaluated by symptom response, quality-of-life, healthcare use, side effects, and cost-effectiveness.
  • Most trials focus on syncope recurrence, neglecting formal quality-of-life assessments.
  • Randomized controlled trials for NCS interventions are scarce, with robust studies showing minimal impact on syncope recurrence.

Purpose of the Study:

  • To review the effectiveness of various treatments for neurocardiogenic syncope.
  • To assess the impact of interventions on syncope recurrence, quality-of-life, and healthcare utilization.
  • To provide evidence-based recommendations for managing neurocardiogenic syncope.

Main Methods:

  • Systematic review of existing literature on neurocardiogenic syncope treatments.
  • Analysis of randomized controlled trials, observational studies, and clinical guidelines.
  • Evaluation of data on symptom recurrence, quality-of-life, side effects, and cost-effectiveness.

Main Results:

  • General advice (hydration, trigger avoidance, counter-pressure maneuvers) and lifestyle changes are favored due to low cost and minimal side effects.
  • Pharmacologic (midodrine, beta-blockers) and device interventions (pacing) show effectiveness in specific patient subgroups.
  • Despite interventions, syncope recurrence remains high in many patients; pacing shows promise for those with asystole during spontaneous syncope.

Conclusions:

  • Lifestyle modifications are recommended for most neurocardiogenic syncope patients due to favorable safety and cost profiles.
  • Pharmacologic and device therapies should be used judiciously in selected patients with clear evidence of benefit.
  • Further research into patient psychology and improved diagnostic methods is needed to enhance quality-of-life and optimize treatment strategies.